Screener
Myriad Genetics MYGN Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Myriad Genetics’s reported figures.
Based on the most recent quarter.
The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 6:05 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000899923-26-000038
FAQ
- What is Myriad Genetics's debt-to-equity?
- Myriad Genetics (MYGN) reported debt-to-equity of 0.6× in Q1 2026.
- How has Myriad Genetics's debt-to-equity changed year-over-year?
- Myriad Genetics's debt-to-equity increased by 180.4% year-over-year, from 0.2× to 0.6×.
- What is the long-term trend for Myriad Genetics's debt-to-equity?
- Over 5 years (2020 to 2025), Myriad Genetics's debt-to-equity has grown at a 11.7% compound annual growth rate (CAGR), from 0.3× to 0.6×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Myriad Genetics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude